metformin has been researched along with Prostatic Hyperplasia in 13 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Prostatic Hyperplasia: Increase in constituent cells in the PROSTATE, leading to enlargement of the organ (hypertrophy) and adverse impact on the lower urinary tract function. This can be caused by increased rate of cell proliferation, reduced rate of cell death, or both.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To assess whether metformin use affects risk of benign prostatic hyperplasia (BPH) by comparing the risk of BPH in men with type 2 diabetes who initiated first-line treatment with either metformin or sulfonylurea monotherapy between 2000 or 2006 in Northern Denmark." | 7.96 | Metformin use and long-term risk of benign prostatic hyperplasia: a population-based cohort study. ( Darvalics, B; Nørgaard, M; Thomsen, RW, 2020) |
| " Questionnaire and linked administrative health data from the Centre for Health Record Linkage and Services Australia were used to identify incident PC, healthcare utilisations, Prostate Specific Antigen (PSA) testing reimbursements and dispensing of metformin and benign prostatic hyperplasia (BPH) prescriptions." | 4.12 | Family history, obesity, urological factors and diabetic medications and their associations with risk of prostate cancer diagnosis in a large prospective study. ( Armstrong, BK; Bang, A; Banks, E; Chiam, K; Egger, S; Nair-Shalliker, V; O'Connell, DL; Patel, MI; Smith, DP; Steinberg, J; Yu, XQ, 2022) |
| "To assess whether metformin use affects risk of benign prostatic hyperplasia (BPH) by comparing the risk of BPH in men with type 2 diabetes who initiated first-line treatment with either metformin or sulfonylurea monotherapy between 2000 or 2006 in Northern Denmark." | 3.96 | Metformin use and long-term risk of benign prostatic hyperplasia: a population-based cohort study. ( Darvalics, B; Nørgaard, M; Thomsen, RW, 2020) |
| " In BPH men, diabetes duration was not significantly related with bladder cancer; but metformin was consistently associated with a significantly lower risk, with adjusted hazard ratio of 0." | 3.79 | Benign prostatic hyperplasia is a significant risk factor for bladder cancer in diabetic patients: a population-based cohort study using the National Health Insurance in Taiwan. ( Tseng, CH, 2013) |
| "Metformin, a first-line treatment for type 2 diabetes mellitus (T2DM), has recently been recognized for its pleotropic anti-proliferative, anti-cancer, and anti-aging effects." | 1.51 | The preventive effect of metformin on progression of benign prostate hyperplasia: A nationwide population-based cohort study in Korea. ( Hong, Y; Lee, S; Won, S, 2019) |
| "Treatment with metformin for 24 hours lowered the G2/M cell population by 43." | 1.46 | Metformin inhibits the proliferation of benign prostatic epithelial cells. ( Ge, R; Johnson, CW; Li, J; Olumi, AF; Rassoulian, C; Wang, Z; Xiao, X, 2017) |
| "Metformin can inhibit the progression of cancer." | 1.40 | Increased FoxM1 expression is a target for metformin in the suppression of EMT in prostate cancer. ( Fu, S; Gao, H; Peng, R; Tang, J; Wang, Y; Yao, B; Zhang, L; Zhang, M, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (7.69) | 29.6817 |
| 2010's | 9 (69.23) | 24.3611 |
| 2020's | 3 (23.08) | 2.80 |
| Authors | Studies |
|---|---|
| Nair-Shalliker, V | 1 |
| Bang, A | 1 |
| Egger, S | 1 |
| Yu, XQ | 1 |
| Chiam, K | 1 |
| Steinberg, J | 1 |
| Patel, MI | 1 |
| Banks, E | 1 |
| O'Connell, DL | 1 |
| Armstrong, BK | 1 |
| Smith, DP | 1 |
| Kaplan, SA | 2 |
| Nørgaard, M | 1 |
| Darvalics, B | 1 |
| Thomsen, RW | 1 |
| Xu, C | 1 |
| Xu, Y | 1 |
| Shen, Z | 1 |
| Zhou, H | 1 |
| Xiao, J | 1 |
| Huang, T | 1 |
| Krüger, HJ | 1 |
| De Wet, R | 1 |
| Blumberg, LH | 1 |
| Weyer, J | 1 |
| Lemke, FG | 1 |
| Kuo, YJ | 1 |
| Sung, FC | 1 |
| Hsieh, PF | 1 |
| Chang, HP | 1 |
| Wu, KL | 1 |
| Wu, HC | 1 |
| Hong, Y | 1 |
| Lee, S | 1 |
| Won, S | 1 |
| Wang, Y | 2 |
| Yao, B | 1 |
| Zhang, M | 1 |
| Fu, S | 1 |
| Gao, H | 1 |
| Peng, R | 1 |
| Zhang, L | 1 |
| Tang, J | 1 |
| Mosli, HH | 1 |
| Esmat, A | 1 |
| Atawia, RT | 1 |
| Shoieb, SM | 1 |
| Mosli, HA | 1 |
| Abdel-Naim, AB | 1 |
| Wang, Z | 1 |
| Xiao, X | 1 |
| Ge, R | 1 |
| Li, J | 1 |
| Johnson, CW | 1 |
| Rassoulian, C | 1 |
| Olumi, AF | 1 |
| Tseng, CH | 1 |
13 other studies available for metformin and Prostatic Hyperplasia
| Article | Year |
|---|---|
Family history, obesity, urological factors and diabetic medications and their associations with risk of prostate cancer diagnosis in a large prospective study.
Topics: Diabetes Mellitus; Humans; Male; Metformin; Obesity; Prospective Studies; Prostatic Hyperplasia; Pro | 2022 |
Re: The Preventive Effect of Metformin on Progression of Benign Prostatic Hyperplasia: A Nationwide Population-Based Cohort Study in Korea.
Topics: Cohort Studies; Humans; Hyperplasia; Male; Metformin; Prostatic Hyperplasia; Republic of Korea | 2020 |
Metformin use and long-term risk of benign prostatic hyperplasia: a population-based cohort study.
Topics: Cohort Studies; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Male; Metformin; Prostatic H | 2020 |
Effects of metformin on prostatic tissue of rats with metabolic syndrome and benign prostatic hyperplasia.
Topics: Animals; Diet, High-Fat; Disease Models, Animal; Hypoglycemic Agents; Insulin Resistance; Insulin-Li | 2018 |
Re: Effects of Metformin on Prostatic Tissue of Rats with Metabolic Syndrome and Benign Prostatic Hyperplasia.
Topics: Animals; Disease Models, Animal; Humans; Male; Metabolic Syndrome; Metformin; Prostatic Hyperplasia; | 2019 |
Atypical presentation of Crimean-Congo haemorrhagic fever: Lessons learned.
Topics: Acidosis; Comorbidity; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Diagnosis, Differential; Dr | 2019 |
Metformin reduces prostate cancer risk among men with benign prostatic hyperplasia: A nationwide population-based cohort study.
Topics: Aged; Aged, 80 and over; Comorbidity; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Incide | 2019 |
The preventive effect of metformin on progression of benign prostate hyperplasia: A nationwide population-based cohort study in Korea.
Topics: Adult; Aged; Cohort Studies; Disease Progression; Humans; Insurance, Health; Male; Metformin; Middle | 2019 |
Increased FoxM1 expression is a target for metformin in the suppression of EMT in prostate cancer.
Topics: Cell Proliferation; Epithelial-Mesenchymal Transition; Forkhead Box Protein M1; Forkhead Transcripti | 2014 |
Metformin Attenuates Testosterone-Induced Prostatic Hyperplasia in Rats: A Pharmacological Perspective.
Topics: Animals; Male; Metformin; Prostatic Hyperplasia; Rats; Testosterone | 2015 |
Metformin inhibits the proliferation of benign prostatic epithelial cells.
Topics: Cell Cycle; Cell Line, Transformed; Cell Proliferation; Cyclin D; Epithelial Cells; Humans; Insulin- | 2017 |
Benign prostatic hyperplasia is a significant risk factor for bladder cancer in diabetic patients: a population-based cohort study using the National Health Insurance in Taiwan.
Topics: Administration, Oral; Adult; Aged; Chi-Square Distribution; Diabetes Mellitus, Type 2; Humans; Hypog | 2013 |
Dutasteride (Avodart) for benign prostatic hyperplasia.
Topics: Abnormalities, Drug-Induced; Administration, Oral; Azasteroids; Biological Availability; Clinical Tr | 2002 |